Introduction
In human assisted reproduction, ovulation response to exogenous recombinant FSH therapy is variable and difficult to predict [1, 2] . The ability to identify patients with potential to develop hyper-response or inadequate response to standard treatment presents a valuable clinical aid.
Several parameters have been postulated as predictors of ovarian response. Ovarian function cannot be measured directly, and the use of serum markers [FSH [Follicle Stimulation Hormone] , inhibin B, 17-β-estradiol and anti-Müllerian hormone [AMH] ] and/or ultrasound variables [ovarian volume, measurement of antral follicles, ovarian stromal blood flow] have proven useful, although limited [3] .
Anti-müllerian hormone [AMH] , also called Mullerian-inhibiting substance MIS [4] , is a dimeric glycoprotein and a member of the transforming growth factor β family that plays a role in the regulation of follicular development [5] . AMH is produced by granulosa cells of the early developing follicles in the ovary, and continues to be expressed in the growing follicles [6] until these follicles have reached a size of 4-6 mm and a differentiation state at which AMH becomes receptive for exogenous FSH [7] , and may be selected for dominance [6] [7] [8] .
Studies in knockout mice for the AMH gene have demonstrated that in the absence of this hormone, follicles are recruited at a faster rate and are more sensitive to FSH [9] , suggesting that serum AMH could inhibit primordial follicle development and be induced by FSH. Moreover, studies in normo-ovulatory women demonstrated an association of the AMH gene polymorphisms, which are located in 19p13. 3, [19p13.3, MIM 600957, Genebank ID 268] , and its receptor AMHR2 [12q13, MIM 600956, Genebank ID 269] with estradiol levels during the follicular phase of the menstrual cycle, suggesting a role in regulating FSH sensitivity [10] . Therefore, genetic variations in AMH and AMHR2 genes may influence the hormonal function in folliculogenesis, resulting in infertility.
Rigon et al. [11] investigated AMH and AMHR2 polymorphisms in women with idiopathic infertility and found that the genotype distribution was significantly different between cases and controls. Riggs et al. [12] demonstrated that AMH can be an ovarian response marker, providing utility in donor selection, and it can also predict the ovarian hyperstimulation syndrome. Previously, these authors showed that AMH was also correlated with ovarian reserve and the number of oocytes retrieved, and thus has a high positive predictive value in relation to age, hormonal levels of FSH, LH, estradiol and inhibin B [13] . However, AMH polymorphisms may affect hormone biological activities, which play an important role in controlling the recruitment and development of follicles [14] . Study of the gene polymorphism that regulate female reproductive function may help to clarify the mechanisms responsible for gonadal function and fertility in humans [11] .
Based on these findings, we aimed to evaluate the polymorphisms G146T/Ile49Ser/ rs10407022 of the AMH gene and A-482G/rs200255, A10G/rs11170555, C1749G/ 
Materials and Methods

Subjects
We performed a prospective cross-sectional study that screened 430 infertile women from the Human Reproduction and Genetics Center of the Faculdade de Medicina do ABC, Santo André, Brazil, between September 2011 and September 2013, who had undergone the first cycle of high complexity assisted reproductive treatment. A total of 186 out of 430 patients (mean age 32.5 ± 3.5 years) met the inclusion criteria: only women with infertility caused by a male factor (n=97), tubal factor (n=59) or idiopathic infertility (n=30) were included in this study. All patients were younger than 38 years old, with normal serum levels of basal FSH (≤10.0 IU/ml), TSH (<4 mIU/L) and prolactin (<25 ng/ml), presence of both ovaries without any morphological abnormalities, normal ovulatory cycles (25-35 days), body mass index (BMI) ≤30, no previous history of poor response and no evidence of endocrine disease, such as polycystic ovary syndrome. Patients with moderate/severe endometriosis (stage III and IV), previous ovarian history or underwent chemo/radiotherapy, low-complexity protocols and cases with severe male factors that underwent surgical procedures for sperm recovery were excluded from the study.
Investigation into the cause of infertility included a hormonal and biochemical profile, testing for sexually transmitted diseases, imaging tests, genetic investigation and/or immunological abnormalities, semen analysis of the partner, hysterosalpingography, hysteroscopy and laparoscopy (performed in all women up to 36 years old, as well as in patients over 36 years of age whenever there were symptoms or abnormalities in the imaging examinations). If no abnormalities were found in these exams, the infertility was classified as idiopathic.
Anatomic tubal abnormalities preventing proper function, such as tubal obstruction, functional changes caused by pelvic inflammatory disease, endometriosis, or previous tubal surgery were considered tube peritoneal factors. These abnormalities were diagnosed by hysterosalpingography and/or laparoscopy.
Male factor was classified when a patient's partner presented an initial concentration of less than 15 million sperm/ml, 5 million/ml rapid progression after sperm processing, or asthenospermia (less than 40% of motile spermatozoa considering rapid progressive, non-progressive or less than 32% if we consider only the rapid progressive sperm), according to the World Health Organization [15] .
A transvaginal ultrasound was used to scan ovaries, before the ovarian stimulation began, on the second day of the menstrual cycle. The antral follicle counting was accomplished in each ovary, and we used the total counting of follicles up to 10 mm. When the presence of polycystic ovaries was diagnosed the patient was excluded of the study.
As approved by the local Research Ethics Committee, the clinical data and peripheral blood samples were collected only after explaining the study aims and obtaining written informed consent.
Ovarian Stimulation
Ovulation was induced by recombinant rFSH an initial daily use of 100 IU or 200 IU that was administered for 10 days, starting on the second day of menstruation. As of the 6 th day and until the 10 th day, the antagonist was also administered. Between day 10 and 11, when the follicles reached a diameter of approximately 17 mm, as determined by transvaginal ultrasound, the patients were given human chorionic gonadotropin (hCG), and on day 13 oocyte retrieval was performed [16] . Regarding controlled ovarian hyperstimulation response, we considered: i) ovarian hyperstimulation syndrome (OHSS), characterized by multiple ovarian follicles (≥20 follicles) together with possible clinical symptoms such as ascites, hematological changes (hemoconcentration), pleural effusion, and liver and/or coagulation abnormalities according to the classification proposed by Golan et al. [17] , as well as ≥4000 IU/ mL of serum estradiol; ii) hyperresponse, when after 6 days of ovarian stimulation with gonadotropins, the 
Genotyping
Five milliliters of peripheral blood was collected in a tube containing EDTA and genomic DNA was extracted from lymphocytes according to a salting out method [18] . The detection of AMH and AMHR2 polymorphisms (G146T/rs10407022, A-482G/rs2002555; A10G/rs11170555; C1749G/rs2071558; G4952A/rs3741664, respectively) was performed using a TaqMan system and real time polymerase chain reaction (PCR), with primers and probes commercially available from Life Technologies (Foster City, CA, USA). Assays were performed using a TaqMan Genotyping Master Mix with 50 to 100 ng of DNA per reaction. The PCR conditions were 40 denaturation cycles of 15 seconds at 95ºC and 1 minute of annealing/extension at 60°C (Table 1) .
Hormonal Measurements
Fresh blood samples were collected on the 2 nd or 3 rd day of the menstrual cycle. Samples were centrifuged at 2000 g for 10 min, aliquoted in a cryopreservation tube and serum samples were stored at -80ºC until AMH, FSH and estradiol measurements were taken.
Basal FSH and estradiol levels were measured by a competition method with a final fluorescent detection (ELFA, Enzyme Linked Fluorescent Assay, Mini-Vidas-BioMerieux, Hazelwood, and Missouri).
AMH measurement was performed in the same laboratory using the same assay by one operator. The AMH serum levels were measured using an enzyme-linked immunosorbent assay (ELISA) using the AMH Gen II kit by Beckman Coulter, Inc (Brea, CA, USA).The measurement was realized by automated Labotech (Alka Technology®). The reading was performed at a wavelength at 450 nm. To calculate the AMH value, we used the point to point method. Values are presented in concentrations of ng/ml (convert to SI units: 1 ng/ ml = 7,14pM). The analytic sensibility was 0.008 ng/ml.
Statistical Analysis
Statistical analyses were accomplished using SPSS for windows version 18.0 (Chicago, IL). To compare the numeric variables and the polymorphism genotypic frequency; we used a Kruskal-Wallis/ANOVA test or a Mann Whitney/Student t-test. These tests were also employed to compare the measurements of serum AMH, AFC with ovarian stimulation outcomes and β-subunit of human chorionic gonadotropin βHCG results.
To verify the association between the genotypes with ovarian stimulation outcomes and the βHCG results, Chi-Square and Fisher tests were used. Spearman's correlation of was applied to verify the association between serum AMH, AFC and the studied quantitative variables.
A model of multinomial logistic regression was adjusted to identify risk factors for ovarian stimulation outcomes. The chi-square test was used to verify if the population was in Hardy Weinberg equilibrium.
The level of significance was considered as p< 0.05, or 5%.
Results
The mean estradiol, AMH and FSH serum levels of patients studied were: 46.1±13.1 pg/ ml, 4.22±2.7 ng/ml, 6.4±2.1 mIU/ml, respectively. 
G146T/rs10407022 polymorphism of the AMH gene
The genotype distribution of AMH G146T/rs10407022 polymorphism was in Hardy Weinberg equilibrium. Association of this polymorphism with AMH, estradiol and FSH serum levels did not show statistical significance (p=0.24; p=0.12; p=0.28, respectively) ( Table 2) .
The genotype distribution according to COH outcomes did not show a positive association, p=0.13, whereas 9.1% (17/186) presented the wild type genotype GG (variant Ile/Ile), 34.4% (64/186) were heterozygotes, and 56.5% (105/186) presented the polymorphic genotype TT (variant Ser/Ser) ( Table 3 ). The frequency of the G allele was n=98 (26.3%), and n=274 (73.7%) for the allele T.
When we compared the genotype distribution according to human reproduction outcomes we did not find any statistically significant differences (AFC, p=0.13; follicles visualized at USG, p=0.13; oocytes retrieved, p=0.07; MII (degree of oocyte maturation), p=0.13; embryos transferred, p=0.56 and frozen embryos, p=0.48), except for the number of embryos produced, p=0.013. The polymorphic genotype TT presented higher mean values of the number of embryos produced (Table 2) . Table 3 . The frequency of the wild type allele was n=284 (76.3%) and the frequency of the polymorphic allele was n=88 (23.7%). Similar to the G146T/Ile49Ser polymorphism, we did not observe any positive association between the A-482G/rs2002555 polymorphism and human reproduction outcomes (AFC, p=0.81; follicles visualized at USG, p=0.13; oocytes retrieved, p=0.24; MII, p=0.20; embryos transferred, p=0.13 and frozen embryos, p=0.69), except for the number of embryos produced, p=0.014 (polymorphic G allele), as shown in Table 4 .
In the analysis of the dominant model, we detected a higher mean value of embryos produced (p=0.005) and embryos transferred (p=0.046) in the presence of the polymorphic genotype GG compared to the A allele. Moreover, the A-482G polymorphism as not statistically significantly associated with the βHCG results, p=0.29.
A10G (rs11170555) polymorphism of the AMHR2 gene
Estradiol and AMH levels were positively associated with A10G genotypes: p=0.019 and p=0.011, respectively. Thereby, polymorphic genotype (GG) demonstrated higher mean values of estradiol and lower mean values of AMH, when compared to the AA genotype. Basal FSH did not display an association, p=0.07 (Table 4) .
COH response was not associated with A10G polymorphism, p=0.35. Of all of the patients, 61.3% (114/186) were wild homozygous, 27.4% (51/186) were heterozygous, and 11.3% (21/186) presented the polymorphic genotype, as shown in Table 3 . The allele A presented a frequency of n=279 (75%) and allele G presented a frequency of n=93 (25%).
The reproductive parameters were not associated with genotypes (AFC, p=0.83; follicles visualized at USG, p=0.27; oocytes retrieved, p=0.69; MII, p=0.53; embryos produced, p=0.09; embryos transferred, p=0.73). Frozen embryo number was correlated with polymorphic genotypes that produced higher rates compared to other genotypes, p=0.046 as shown in Table 4 .
Moreover, A10G polymorphism resulted in statistically significant for βHCG, thereby patients with polymorphic genotype presented higher frequencies of positive βHCG, p=0.05.
C1749G (rs2071558) polymorphism of the AMHR2 gene
Basal FSH, AMH and estradiol did not show a positive association with C1749G polymorphism, p=0.97, p=0.37, p=0.07, respectively, as well as G146T and A-482G polymorphisms (Table 4) . Table 3 . The allele frequency was n=312 (83.9%) for allele C and n=60 (16.1%) for allele G.
In contrast to other polymorphisms, we detected a positive association between follicles visualized at USG, p=0.049 and MII, p=0.041, while the other variables were not correlated (AFC, p=0.37; oocytes retrieved, p=0.07; embryos produced, p=0.06; embryos transferred, p=0.62 and frozen embryos, p=0.27). Polymorphic genotype carriers had higher mean values than wild type and heterozygous genotypes (Table 4) .
For pregnancy rate, C1749G polymorphism could not predict βHCG results, p=0.92.
G4952A (rs3741664) polymorphism of the AMHR2 gene
Wild type genotypes had significantly higher basal FSH levels compared to that of heterozygous genotypes, p=0.03. However, estradiol and AMH serum levels were not positively correlated, with the G4952A polymorphism p=0.72 and p=0.15, respectively (Table 4) .
As was the case for all other polymorphisms, G4952A could not predict COH response, p=0.33.
The frequency of genotypes were as follows: 71.5% (133/186) were wild type homozygous and 28.5% (53/186) were heterozygous. None of the patients presented the polymorphic genotype (Table 3 ). The allele frequency was 85.8% for the wild type allele (n=319) and 14.2% for the polymorphic allele (n=53).
G4952A polymorphism is also not a good predictor of assisted reproduction outcomes: we did not observe a statistically significant correlation with any of the variables studied (AFC, p=0.41; follicles visualized at USG, p=0.10; oocytes retrieved, p=0.75; MII, p=0.22; embryos produced, p=0.63; embryos transferred, p=0.73 and frozen embryos, p=0.53). As shown in Table 4 .
Thus, the G4952A polymorphism did not demonstrate a positive association with βHCG results, p=0.83.
Serum AMH as a predictor of assisted reproduction outcomes
In a comparison of serum AMH levels with assisted reproductive parameters, we verified that all variables were statistically significant: AFC, p<0.001; follicles visualized at USG, p=0.001; oocytes retrieved, p=0.021; MII, p=0.008; number of frozen embryos, p=0.012; with the exception of number of embryos, p=0.158 and number of embryos transferred, p=0.712. Results are shown in Table 5 .
Regarding the COH outcomes, we can attest that the AMH levels in patients who had suffered OHSS were almost double that of other groups; thus, the minimum value of AMH detected in these patients was almost four times higher compared to other patients, p<0.001. However, it was not possible to stipulate a cut-off value for OHSS, once good responder patients had a minimum of 0.5 ng/ml and a maximum of 17.5 ng/ml of serum AMH and the values of the two groups overlapped.
To identify if AMH is a predictor of COH response, a multinomial logistic regression model was performed. According to the results, for the growth of one unit of AMH (1.0 ng/ ml), the chance of belonging to the hyper response group increased by 1.28 times, and the chance of belonging to the OHHS group increased by 1.36 times.
As for poor responders the chance of belonging to the hyper response group increased by 1.28, and the chance of belonging to the OHSS group increased by 1.37 times.
AFC as a predictor of assisted reproduction outcomes
When we use antral follicle counting as a predictor of COH response, AFC was positively correlated with hyperstimulation syndrome (p=0.005), as well as AMH. Considering assisted reproduction outcomes, we observed that AFC was positively correlated only with the number of frozen embryos, p=0.004. However, the other parameters were not correlated
(follicles visualized at USG, p=0.108; oocytes retrieved, p=0.49; MII, p=0.102; number of embryos produced, p=0.182; embryos transferred, p=0.904) ( Table 5 ). βHCG results also had a negative correlation, p=0.693.
Discussion
To the best of our knowledge, this is the first study to associate AMH and AMHR2 polymorphisms with AMH, estradiol, FSH serum levels, COH response and assisted reproduction outcomes in a Brazilian population.
Durlinger et al. [9] demonstrated that AMH knockout mice had follicles recruited at a faster rate than controls, and that they became more sensitive to FSH. AMH and AMHR2 polymorphisms contribute to the individual variation in the FSH ovary threshold [19] . These polymorphisms appear to affect hormone biological activities, thus affecting follicle recruitment and development [14] .
Kevenaar et al. [10] developed an association study with Dutch and German cohorts of normo-ovulatory women. The results revealed that, in Dutch women, carriers of the Ser/Ser variant (TT genotype) of the G146T/rs10407022 polymorphism had significantly higher estradiol levels on day 3 of their menstrual cycle when compared to women with the others genotypes. Subsequently, the Dutch and German cohorts were analyzed together. In the combined cohort, carriers of the Ser/Ser variant, again, had higher estradiol levels; however, this change was not associated with serum AMH and FSH. In the present study, we observed that only the A10G/rs11170555 polymorphism of AMHR2 was associated with estradiol and AMH serum levels. Thus, carriers of polymorphic genotypes had higher mean estradiol levels, and lower serum AMH levels.
In contrast, a study with Chinese infertile women did not find a correlation between estradiol serum levels and G146T/Ile49Ser/rs10407022 polymorphism [20] . Similar to the results reported by Xu et al. [20] , the present study did not find such correlations between A-482G, C1749G and G4952A polymorphisms of the AMHR2 gene. In the same Dutch and German cohorts, it was shown that AMHR2 genotypes were significantly associated with estradiol serum levels during the early follicular phase of the menstrual cycle [10] .
None of these studies found an association between basal FSH and AMH and AMHR2 genes. We demonstrated that only the polymorphism G4952A/rs3741664 was significantly associated with basal FSH, because non mutation carriers had higher FSH levels.
The Ser/Ser variant [TT genotype] is less effective in reducing individual FSH sensitivity of antral follicles. In vitro studies have demonstrated that Ser/Ser protein bioactivity is reduced compared with the Ile/Ile protein, and because of that, the T/Ser allele also had a lower total follicle number compared to the other groups [10] . However, we did not find any interconnection among G146T/Ile49Ser/rs10407022 or polymorphisms of the AMHR2 gene and the antral follicle counting. Nevertheless, the C1749G polymorphism of the AMHR2 gene showed a statistically significant difference, so that carriers of the polymorphic genotype had more follicles visualized by ultrasound and a better degree of oocyte maturation.
The G146T/rs10407022 polymorphism is located in the AMH gene promoter region, leading to an amino acid substitution in the protein: isoleucine to serine in position 49 of the AMH protein [Ile49Ser]. This region is responsible for protein stability and folding. Thus, mutations within the promoter region could affect AMH biosynthesis or bioactivity. This mutation in the AMH gene can inactivate the protein. The G146T/Ile49Ser/rs10407022 polymorphism did affect its bioactivity, but not the processing of AMH [21] . The reason why AMH and AMHR2 polymorphisms can predict the number of embryos produced, while AMH serum levels could not predict this same variable are explained by our results,. The presence of a serine at amino acid position 49 likely alters the protein folding, making the protein less bioactive in comparison to the protein that has isoleucine at this position [21] .
Kevenaar et al. [10] suggested that AMHR2 polymorphic genotype GG can result in diminished AMH signaling, and because of its location (promoter region), it may cause disequilibrium with other SNPs. The diminished AMH signaling may result in increased primordial follicle recruitment. In a study conducted by Yassin et al. [22] , it was found that the oocyte retrieval rate of the GG genotype of the AMHR2A-482G/rs2002555 was statistically lower than in the control group, suggesting that a homozygous mutation (-482GG genotype) may cause poor follicular development. However, they did not find a positive association with AMH G146T/Ile49Ser/rs10407022 polymorphism. We showed that the number of embryos produced were statistically associated with the polymorphic genotype (AMH 146TT and AMHR2 -482GG) in cases of AMH G146T/Ile49Ser/rs10407022 and AMHR2 A-482G/rs2002555 polymorphisms. We also showed that the AMHR2 polymorphism A10G/ rs11170555 was positively associated with the number of frozen embryos.
A mutation in the AMH gene and in its receptor, which prevents the AMH from properly exerting its function, would influence the inhibitory action on FSH. Therefore, it will be recruited by more follicles, and thus the number of embryos produced, and possibly frozen, would be relatively high.
There have been few studies reported that compared AMH and AMHR2 polymorphisms and assisted reproduction outcomes. Moreover, most of those studies only analyzed the polymorphisms G146T/Ile49Ser/rs10407022 of the AMH gene and A-482G/rs2002555 of theAMHR2 gene.
Furthermore, it has been shown that allele frequencies of the A-482G polymorphism were statistically significantly increased in Italian infertile patients compared with controls. The AMH G146T/Ile49Ser/rs10407022 polymorphism was associated with an increased frequency of T/Ser allele in infertile patients compared to controls, suggesting that variants of AMH and AMHR2 genes appear to be associated with infertility [11] .
The first study to indicate that AMH could predict COH response was reported by Seifer et al. [23] . They studied 107 infertile women that were divided into two groups: those who had ≤6 oocytes (n=28) and ≥11 oocytes retrieved (n=79). The results revealed a significant positive correlation between AMH and the number of oocytes retrieved, as well as mature oocytes. More recently, a study conducted on 81 infertile women from the Gaza Strip compared AMH with age, total number of oocytes, number of mature oocytes and number of embryos. The authors demonstrated that AMH was correlated with all of these variables, and they also showed that mean levels of AMH indicated a progressive increase in parallel to the total number of oocytes in poor, good and high responders [22] .
In agreement with these studies, we demonstrated that serum AMH level is positively interconnected with AFC, follicles visualized at USG, oocytes retrieved, MII, and number of frozen embryos. However, AMH failed to predict pregnancy. A review by Broekmans et al [3] concluded that markers of ovarian reserves, including AMH, were not good predictors of pregnancy in IVF cycles. To confirm that AMH is a better marker of COH response and IVF outcomes, we compared it with AFC. Our results confirm previously reported findings [24] [25] [26] that attested that AFC is less effective than AMH in predicting IFV outcomes; AFC was only associated with number of frozen embryos. La Marca et al. [27] indicated that AMH has primarily been related to assisted reproduction because of its strong association with oocyte yield after COH. Therefore, this hormone should be capable of predicting ovarian response [24, [28] [29] [30] .
Several studies have presented AMH as a predictor of ovarian response [24, 31, 32] . The ability to predict early ovarian response to COH would provide the opportunity to obtain essential information to improve further cycles [33] . A meta-analysis including 1,500 patients from nine studies established that AMH is a good predictor of excessive ovarian response [25] . Moreover, Lee et al. [28] reported that AMH is a better predictor than age, BMI, basal FSH or inhibin B. Our results corroborate with previous reports in the literature. We showed that AMH is strongly associated with OHSS, and for every time that normal responders increase 1.0 ng/ml of AMH, the chance of belonging to the OHSS group also increased by 1.28 times. This chance is 1.37 times when the reference is poor responder patients. Nevertheless, it is difficult to define a cutoff value for OHSS, especially for the lack of reference values for this hormone in the literature.
